SinoMab BioScience (HKSE:03681) ROCE % : -30.02% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SinoMab BioScience's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.02%.

SinoMab BioScience ROCE % Historical Data

The historical data trend for SinoMab BioScience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience ROCE % Chart

SinoMab BioScience Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-44.21

-11.05

-28.52

-30.10

-31.26

SinoMab BioScience Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial							-35.48	-31.00	-32.27	-33.33	-30.02

SinoMab BioScience ROCE % Calculation

SinoMab BioScience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-258.708	/	( ( (1126.037 - 209.262)	+	(927.29 - 188.837) )	/ 2 )
	=	-258.708	/	( (916.775	+	738.453)	/ 2 )
	=	-258.708	/	827.614
	=	-31.26 %

SinoMab BioScience's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-231.078	/	( ( (992.484 - 191.238)	+	(927.29 - 188.837) )	/ 2 )
	=	-231.078	/	( ( 801.246	+	738.453 )	/ 2 )
	=	-231.078	/	769.8495
	=	-30.02 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

SinoMab BioScience (HKSE:03681) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SinoMab BioScience ROCE % Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SinoMab BioScience (HKSE:03681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG

Website

https://www.sinomab.com

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Executives

Hainan Haiyao Co. Ltd.	2101 Beneficial owner
Liu Wenyi	2201 Interest of corporation controlled by you
Leung Shui On	2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited	2101 Beneficial owner
Skytech Technology Limited	2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch	2106 Person having a security interest in shares
Xu Sijia	2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She	2106 Person having a security interest in shares
Apricot Oversea Holdings Limited	2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si	2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si	2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines